Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication

Basit Öğe Kaydı
dc.authoridRESAT, MEHMET/0000-0001-8063-4836
dc.authorwosidDAĞLI, Şeyda Nur/HKW-2798-2023
dc.contributor.authorOzgocer, Tuba
dc.contributor.authorDagli, Seyda N.
dc.contributor.authorCeylan, Mehmet R.
dc.contributor.authorDisli, Faruk
dc.contributor.authorUcar, Cihat
dc.contributor.authorYildiz, Sedat
dc.date.accessioned2024-08-04T20:50:51Z
dc.date.available2024-08-04T20:50:51Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe first aim of the study was to analyze the change in antibody titer at 15-day intervals until 60 days postsymptom onset (PSO). The second aim was to analyze the relationship between antibody titer and symptom grade, gender, age, body mass index (BMI), medications, vitamin supplements, and herbal therapies. Blood samples were collected from 43 patients (5 mild, 21 moderate, 17 severe diseases), 18 women (41.9%), and 25 men (58.1%), on 15, 30, 45, and 60 days PSO after COVID-19 infection. The serum antibody titers were determined by measuring the COVID-19 immunoglobulin G (IgG) antibodies by enzyme-linked immunoassay (ELISA). Associations between the duration of symptoms, demographic and clinical parameters, medications and vitamins used, and herbal therapies were evaluated by interviewing the participants. Within the first 15 days of illness, 81.4% of the patients were positive. From Day 45 PSO, seropositivity was 89.5%. The anti-SARS-CoV-2 antibody titers were statistically higher in men than women at all times (p < 0.01). Antibody titer was higher in older participants compared to younger participants (p < 0.02). Plaquenil or favipiravir use did not affect antibody response (p > 0.05). Men had a higher fever (p = 0.006), shortness of breath (p = 0.004), and chest pain (p = 0.03) than women. We found powerful antibody response by 60 days PSO, as well as higher antibody response and severity of symptoms in the men gender. Data also showed that SARS-CoV-2 antibodies are higher in individuals with older age, whereas BMI, concomitant chronic disease, and medications had no effect on antibody titers.en_US
dc.identifier.doi10.1002/jmv.27452
dc.identifier.endpage1418en_US
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.issue4en_US
dc.identifier.pmid34766646en_US
dc.identifier.scopus2-s2.0-85119187905en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1412en_US
dc.identifier.urihttps://doi.org/10.1002/jmv.27452
dc.identifier.urihttps://hdl.handle.net/11616/100310
dc.identifier.volume94en_US
dc.identifier.wosWOS:000719882500001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectageen_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19 symptomen_US
dc.subjectgenderen_US
dc.subjectIgG antibody titeren_US
dc.titleAnalysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medicationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu